RESUMO
Zika virus (ZIKV), an emerging arthropod-borne virus (arbovirus) of the Flaviviridae family, is a current issue worldwide, particularly because of the congenital and neurological syndromes associated with infection by this virus. As the initial clinical symptoms of all diseases caused by this group are very similar, clinical diagnosis is difficult. Furthermore, laboratory diagnostic efforts have failed to identify specific and accurate tests for each virus of the Flaviviridae family due to the cross-reactivity of these viruses in serum samples. This situation has resulted in underreporting of the diseases caused by flaviviruses. However, many companies developed commercial diagnostic tests after the recent ZIKV outbreak. Moreover, health regulatory agencies have approved different commercial tests to extend the monitoring of ZIKV infections. Considering that a specific and sensitive diagnostic method for estimating risk and evaluating ZIKV propagation is still needed, this review aims to provide an update of the main commercially approved serological diagnostics test by the US Food and Drug Administration (FDA) and Brazilian National Health Surveillance Agency (ANVISA). Additionally, we present the technologies used for monoclonal antibody production as a tool for the development of diagnostic tests and applications of these antibodies in detecting ZIKV infections worldwide.
RESUMO
Zika virus (ZIKV), an emerging arthropod-borne virus (arbovirus) of the Flaviviridae family, is a current issue worldwide, particularly because of the congenital and neurological syndromes associated with infection by this virus. As the initial clinical symptoms of all diseases caused by this group are very similar, clinical diagnosis is difficult. Furthermore, laboratory diagnostic efforts have failed to identify specific and accurate tests for each virus of the Flaviviridae family due to the cross-reactivity of these viruses in serum samples. This situation has resulted in underreporting of the diseases caused by flaviviruses. However, many companies developed commercial diagnostic tests after the recent ZIKV outbreak. Moreover, health regulatory agencies have approved different commercial tests to extend the monitoring of ZIKV infections. Considering that a specific and sensitive diagnostic method for estimating risk and evaluating ZIKV propagation is still needed, this review aims to provide an update of the main commercially approved serological diagnostics test by the US Food and Drug Administration (FDA) and Brazilian National Health Surveillance Agency (ANVISA). Additionally, we present the technologies used for monoclonal antibody production as a tool for the development of diagnostic tests and applications of these antibodies in detecting ZIKV infections worldwide.(AU)
Assuntos
Infecção por Zika virus/diagnóstico , Testes Sorológicos , Comércio , Anticorpos Monoclonais/análise , Anticorpos Monoclonais/química , Zika virusRESUMO
Zika virus (ZIKV), an emerging arthropod-borne virus (arbovirus) of the Flaviviridae family, is a current issue worldwide, particularly because of the congenital and neurological syndromes associated with infection by this virus. As the initial clinical symptoms of all diseases caused by this group are very similar, clinical diagnosis is difficult. Furthermore, laboratory diagnostic efforts have failed to identify specific and accurate tests for each virus of the Flaviviridae family due to the cross-reactivity of these viruses in serum samples. This situation has resulted in underreporting of the diseases caused by flaviviruses. However, many companies developed commercial diagnostic tests after the recent ZIKV outbreak. Moreover, health regulatory agencies have approved different commercial tests to extend the monitoring of ZIKV infections. Considering that a specific and sensitive diagnostic method for estimating risk and evaluating ZIKV propagation is still needed, this review aims to provide an update of the main commercially approved serological diagnostics test by the US Food and Drug Administration (FDA) and Brazilian National Health Surveillance Agency (ANVISA). Additionally, we present the technologies used for monoclonal antibody production as a tool for the development of diagnostic tests and applications of these antibodies in detecting ZIKV infections worldwide.(AU)
Assuntos
Vigilância Sanitária , Testes Sorológicos/métodos , Flaviviridae , Flavivirus , Zika virus , Anticorpos , Anticorpos MonoclonaisRESUMO
Experimental studies on atherosclerosis are crucial for investigating its pathophysiology, defining new therapeutic targets, and developing new drugs and diagnostic tools. Thus, many imaging markers have been developed and introduced in experimental studies. The main advantage of these new tools is that they allow the noninvasive diagnosis of atherosclerotic vascular disease. Here, we describe the cloning, expression, purification, and stabilization of a chimeric protein specifically designed to probe cells and tissues for the presence of LDL(-), a relevant marker of atherosclerosis. The DNA sequence that encodes the anti-LDL(-) scFv, previously obtained from a hybridoma secreting an anti-LDL(-) monoclonal antibody, was inserted into the bacterial vector pET-28a(+) in tandem with a DNA sequence encoding GFP. The recombinant protein was expressed in high yields in E. coli as inclusion bodies. The applicability of GFP-scFv was assessed by ELISA, which determined its affinity for LDL(-) and confocal microscopy, that showed macrophage uptake of the protein along with LDL(-). In conclusion, our data suggest that the anti-LDL(-) GFP-scFv chimeric protein could be useful in studies on atherogenesis as well as for developing diagnostic tools for atherosclerosis.
Assuntos
Biomarcadores/metabolismo , Proteínas de Fluorescência Verde/metabolismo , Lipoproteínas LDL/metabolismo , Proteínas Recombinantes de Fusão/metabolismo , Anticorpos de Cadeia Única/metabolismo , Animais , Aterosclerose/metabolismo , Linhagem Celular Tumoral , Endocitose , Escherichia coli/metabolismo , Proteínas de Fluorescência Verde/química , Proteínas de Fluorescência Verde/farmacocinética , Camundongos , Imagem Molecular/métodos , Ligação Proteica , Proteínas Recombinantes de Fusão/química , Proteínas Recombinantes de Fusão/farmacocinética , Anticorpos de Cadeia Única/química , Anticorpos de Cadeia Única/farmacocinéticaRESUMO
PURPOSE: To investigate the influence of the Factor H (CFH) Tyr4°²His polymorphism on the plasma levels of the alternative pathway proteins CFH, C3, Factor B (FB), Factor D (FD), and Factor I (FI) and the inflammatory marker C-reactive protein (CRP) in 119 patients with age-related macular degeneration (AMD) and 152 unrelated control individuals. METHODS: Patients with AMD and the control group were separated according to CFH polymorphism, age, and gender. Plasma complement proteins and CRP concentrations were determined with enzyme-linked immunosorbent assay, immunodiffusion, or nephelometry. RESULTS: Significant differences in the concentrations of FD and FI were observed between the patients with AMD and the control individuals. We observed significantly reduced FD plasma levels in patients with AMD. We also identified a significant decrease in CFH plasma levels in female patients with AMD in relation to female controls. Plasma FI levels were significantly increased in patients with AMD compared to the control group. Regarding gender, a significant increase in FI plasma levels was observed in male patients. Finally, we found no significant correlation between the CFH Tyr(402)His polymorphism and the CFH, C3, FB, FD, FI, and CRP plasma levels. CONCLUSIONS: Patients with AMD present altered levels of FD and FI in a manner independent of this CFH polymorphism, and gender apparently contributes to the plasma levels of these two proteins in patients with AMD and control individuals.
Assuntos
Fator H do Complemento/genética , Via Alternativa do Complemento/genética , Degeneração Macular/genética , Idoso , Idoso de 80 Anos ou mais , Proteína C-Reativa/metabolismo , Estudos de Casos e Controles , Complemento C3/metabolismo , Fator B do Complemento/metabolismo , Fator D do Complemento/metabolismo , Fator H do Complemento/metabolismo , Fator I do Complemento/metabolismo , Ensaio de Imunoadsorção Enzimática , Feminino , Genótipo , Humanos , Degeneração Macular/sangue , Masculino , Pessoa de Meia-Idade , Polimorfismo de Nucleotídeo Único , Fatores SexuaisRESUMO
Leptospirosis isazoonosis caused by pathogenic bacteria from the genus Leptospira.Thediseaserepresents a seriouspublic health problem inunderdeveloped tropical countries.Leptospire sinfecthosts throughsmallabrasions in the skin or mucousmembranesand they rapidly disseminateto target organs.Thecapacityof some pathogenic leptospira lstrains toacquire thenegative complementregulators factorH(FH)andC4bbindingpro teincorrelateswith their abilityto survivein humans e rum.Inthis study weasses sed the functional consequences oft heagemaculardegeneration-associatedpolymorphismFHHis402orFHTyr402onFH Leptospira interactions.Inbinding assaysusing sub-satura tingamounts ofFH, theFHTyr402 variant interacted with all the strainstested more stronglythanthe FHHis402variant.Athigher concentrations, differences tendedto disappear. We then compared co factor activities displayed by FH. His402and FH Tyr402 bound tothe surface ofL.interrogans. Bothvariantsex ibit similar activity as cofactors for FactorI mediated cleavage of C3b,thusindicating that they do not differin their capacity toregulate the complement cascade.
Assuntos
Fator H do Complemento/análise , Fator H do Complemento/imunologia , Leptospira interrogans serovar pomona/genética , Leptospira interrogans serovar pomona/imunologia , Leptospira/imunologia , Fator H do Complemento/isolamento & purificação , Polimorfismo Genético/imunologiaRESUMO
Leptospirosis is a zoonosis caused by pathogenic bacteria from the genus Leptospira. The disease represents a serious public health problem in underdeveloped tropical countries. Leptospires infect hosts through small abrasions in the skin or mucous membranes and they rapidly disseminate to target organs. The capacity of some pathogenic leptospiral strains to acquire the negative complement regulators factor H (FH) and C4b binding protein correlates with their ability to survive in human serum. In this study we assessed the functional consequences of the age macular degeneration-associated polymorphism FH His4°² or FH Tyr4°² on FH-Leptospira interactions. In binding assays using sub-saturating amounts of FH, the FH Tyr4°² variant interacted with all the strains tested more strongly than the FH His4°² variant. At higher concentrations, differences tended to disappear. We then compared cofactor activities displayed by FH His4°² and FH Tyr4°² bound to the surface of L. interrogans. Both variants exhibit similar activity as cofactors for Factor I-mediated cleavage of C3b, thus indicating that they do not differ in their capacity to regulate the complement cascade.